Intelomed Named Tech 50 Finalist As Innovator Of The Year For Healthcare IT

(Click here for details)
Visit Intelomed at InteloMed.com

PITTSBURGH, PA--(Marketwired - September 10, 2015) -

InteloMed, Inc., an emerging leader in non-invasive cardiovascular monitoring and developer of the CVInsight™ Platform, a solution for non-invasive monitoring of the cardiovascular system, announced today that the Pittsburgh Technology Council has named it as a Tech 50 Finalist as Innovator of the Year for Healthcare IT.

The Pittsburgh Technology Council’s Annual Tech 50 Awards recognize southwestern Pennsylvania’s transformative technology centers of excellence with tech companies at all stages of growth.

“The Tech 50 Awards honor those companies that demonstrated the strongest growth and advancement in product or sales success, financial strength, corporate citizenship, job growth and retention and innovative product or technology,” said Audrey Russo, President and CEO, Pittsburgh Technology Council. “We are excited to announce the category winners at the awards gala this fall. It is truly a night to celebrate our region’s technology companies and the contributions they have made to our economic vitality.”

“InteloMed is honored to be recognized as a Tech 50 Finalist for Healthcare IT”, commented Jill Schiaparelli, President and CEO of InteloMed. “Our non-invasive monitoring platform, CVInsight™, provides new ways of looking at traditional cardiovascular metrics, allowing clinicians to more effectively manage their patients. We are proud to be recognized as an innovator in this area.”

For more information on Tech 50 Finalists, visit http://www.pghtech.org/events/tech-50.aspx. For more information on the Pittsburgh Technology Council, visit www.pghtech.org.

About InteloMed
InteloMed is redefining the standard of care in intelligent cardiovascular monitoring in hospitals and health care facilities through its non-invasive CVInsight™ Platform. The CVInsight™ Platform provides real-time insights on the stress level of the cardiovascular system to inform clinical decisions which, as part of a well-managed care plan, may lead to earlier detection of cardiovascular decline, earlier intervention, decreased hospitalization and improved patient outcomes. The CVInsight™ Platform has functionality in hospital and outpatient settings and has clinical applications in multiple areas including hemodialysis, heart failure, and the surgical continuum. InteloMed is headquartered in Wexford, PA.
For more information, visit us at www.InteloMed.com.

Safe Harbor Statement
Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.